MENU
 JPMA
  • Directions
  • Japanese
  • About JPMA

    About JPMA: Top

    • Message from the President
    • Overview of JPMA
    • Policies and Activities
    • Voluntary Standards
    • Vision, Policy Proposals
    • Organization
    • Member Companies
  • About Medicines

    About Medicines: Top

    • Medication Guide for the General Public
    • Clinical Trial Information
    • Working Together with Patients
  • Committee Updates

    Committee News Top

    • Code Compliance Committee
    • Pharmaceutical Industrial Policy Committee
    • Distribution Improvement Committee
    • Drug Evaluation Committee
    • Quality & Technology Committee
    • Biopharmaceutical Committee
    • Regulatory Affairs Committee
    • Intellectual Property Committee
    • R & D Committee
    • International Affairs Committee
    • Public Affairs Committee
    • Patient Cooperation Committee
    • ICH Project
    • APAC Project
    • Consumer Consultation Review Committee
    • Environmental Issue Committee
  • Newsletter
  • Newsroom

    Newsroom Top

    • News Releases and Announcements
    • JPMA Newsletter
    • Updates
    • Publications
    • Events
    • JPMA Video Content and Advertisements
  • The Office of Pharmaceutical Industry Research
Close
 JPMA

Return to Top

  • Patients and the General Public (About Medicines)
    Patients and the General Public (About Medications) Top
    • Medication Guide for the General Public
    • Clinical Trial Information
    • Working Together with Patients
  • Committee Updates
    Committee News Top
    • Code Compliance Committee
    • Pharmaceutical Industrial Policy Committee
    • Distribution Improvement Committee
    • Drug Evaluation Committee
    • Quality & Technology Committee
    • Biopharmaceutical Committee
    • Regulatory Affairs Committee
    • Intellectual Property Committee
    • R & D Committee
    • International Affairs Committee
    • Public Affairs Committee
    • Patient Cooperation Committee
    • ICH Project
    • APAC Project
    • Consumer Consultation Review Committee
    • Environmental Issue Committee
  • About JPMA
    About JPMA: Top
    • Message from the President
    • Overview of JPMA
    • Policies and Activities
    • Voluntary Standards
    • Vision, Policy Proposals
    • Organization
    • Member Companies
  • Policies and Activities
    Policies & Activities Top
    • Business Policy, Business Plan, and Implementation Plan
    • Committee Activities
    • Convention on Biological Diversity
  • Voluntary Standards
    Voluntary Standards Top
    • Code of Conduct
    • JPMA Code of Practice
    • Transparency Guideline for the Relation between Corporate Activities and Medical Institutions
    • Transparency Guideline for Relationships Between Corporate Activities and Patient Organizations
    • Guidelines for the Preparation of Summaries of Product Characteristics for Prescription Drugs (Abbreviation: Preparation Guidelines)
    • Clinical Research
    • Basic Principles and Guidelines for Action on Biodiversity
    • Guidelines on Fair Competition at Meetings of the Japan Pharmaceutical Manufacturers Association
    • Agreements, Manuals, and Guidelines
  • Newsroom
    Newsroom Top
    • News Releases and Announcements
    • JPMA Newsletter
    • Updates
    • Publications
    • Events
    • JPMA Video Content and Advertisements
  • The Office of Pharmaceutical Industry Research  Opens in a new window
  • Social Media Policy
  • Website Terms of Use
  • Access
  • Japanese
  • Home
  • Committee Updates
  • Drug Evaluation Committee
  • Drug Evaluation Committee Symposium
  • Materials for "Workshop for Practitioners on Electronic Data Submission at the Time of Application" in FY2022

Drug Evaluation Committee Materials for "Workshop for Practitioners on Electronic Data Submission at the Time of Application" in FY2022

Mar 02, 2023

  • 00_Program (170KB)
  • 01_Examination of the relationship between explanatory materials (Form A) and data guides for electronic data at the time of application (1.84MB)
  • 02. Proposal of Best Practice for electronic data submission using data prepared by other companies (3.94MB)
  • 03_Electronic Data Submission for PPK Analysis: What You Need to Know (3.84MB)
  • 04_Questionnaire results on the impact of eCTD v4.0 on the electronic data submission process (886KB)
  • 05. Points that CDISC staff of CROs should pay attention to when complying with eCTD V4.0 (862KB)
  • 06_Current Status and Points to Consider Concerning Electronic Data Submission of Applications (840KB)
  • 07_Update on eCTD v4 and Gateway (1.96MB)
  • 08_Introduction of internal process study for electronic data submission of applications with eCTD Ver. 4.0 (1.31MB)
  • 09_Best Practices for Early Transition to Online Submission as Communicated by Regulatory Affairs Operations Involved in Gateway Submission from the Early Days (1.38MB)

Return to the Drug Evaluation Committee Symposium Top Page

Share this page

  • Post
  • Share

TOP

Site Search

  • Home
  • Committee Updates
  • Drug Evaluation Committee
  • Drug Evaluation Committee Symposium
  • Materials for "Workshop for Practitioners on Electronic Data Submission at the Time of Application" in FY2022
  • JPMA PR and Communications Activities
  • Pharmaceutical Research Institute
  • List of Non-Financial Information Disclosures by Member Companies
  • STOP AMR
  • About the JPMA
  • Policies and Activities
  • Voluntary Standards
  • Global Health
  • Newsroom
  • Patients and the General Public (About Medicines)
  • Clinical Trial Information
  • Committee Updates
  • JapanesePage will open in a new window.
  •  x
  •  Facebook
  •  YouTube
  • Site Map
  • Website Terms of Use
  • Basic Policy on Information Security
  • Social Media Policy
  • Links
  • Accessibility Policy
  • PRAISE-NET Login

© Japan Pharmaceutical Manufacturers’
’ Association (JPMA). All rights reserved.

Notification

This website uses automatic translation.
The translated content may not always be fully consistent with the original Japanese content.